**Supplemental Table 2**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Days** | **Metoprolol** | | **Atenolol** | | **Propranolol** | |
| **Canine colonoid monolayer** |  | **Mean** | **SD** | **Mean** | **SD** | **Mean** | **SD** |
| **1** | 13.26 | 3.30 | 18.03 | 5.40 | 10.58 | 2.91 |
| **2** | 79.19 | 23.40 | 83.54 | 22.71 | 71.83 | 15.82 |
| **3** | 512.42 | 200.30 | 547.54 | 200.73 | 441.38 | 209.88 |
| **4** | 1152.00 | 102.40 | 1033.59 | 201.67 | 1270.17 | 117.52 |
| **5** | 1946.83 | 219.80 | 1843.28 | 118.78 | 1665.94 | 148.29 |
| **6** | 2444.75 | 107.50 | 2232.74 | 126.62 | 2529.14 | 172.05 |
| **7** | 2724.61 | 127.39 | 2924.34 | 166.15 | 2605.07 | 130.83 |
| **8** | 3033.20 | 100.71 | 3217.01 | 275.67 | 3136.60 | 237.59 |
| **9** | 3595.95 | 100.51 | 3659.72 | 121.17 | 3711.78 | 112.31 |
| **10** | 4006.24 | 250.44 | 4211.72 | 251.65 | 4223.69 | 224.59 |
| **11** | 4099.73 | 357.43 | 4344.74 | 358.71 | 4238.37 | 253.15 |
| **12** | 3977.80 | 341.96 | 4205.32 | 342.46 | 4260.19 | 449.26 |
| **13** | 3032.24 | 356.66 | 3367.85 | 96.98 | 3402.98 | 87.70 |
| **14** | 2541.86 | 315.42 | 2842.84 | 310.04 | 2703.76 | 211.70 |
| **15** | 1796.67 | 196.58 | 2121.39 | 76.46 | 1963.67 | 156.75 |

**Supplemental Table 2A.** Continuous TEER analysis over 15 days was used to assess the integrity of each colonoid monolayer (n = 18 used for each drug study) (canine colonoid-derived monolayers with IDs Colonoid#M1 to Colonoid#M54 were used).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Days** | **Metoprolol** | | **Atenolol** | | **Propranolol** | |
| **Caco-2 monolayer** |  | **Mean** | **SD** | **Mean** | **SD** | **Mean** | **SD** |
| **1** | 34.90 | 10.49 | 28.45 | 5.44 | 31.56 | 3.55 |
| **3** | 178.04 | 30.09 | 161.35 | 23.92 | 172.69 | 28.43 |
| **4** | 239.66 | 12.36 | 244.60 | 18.88 | 228.29 | 8.71 |
| **6** | 280.12 | 28.32 | 265.91 | 29.47 | 253.44 | 20.01 |
| **8** | 278.24 | 21.32 | 288.21 | 22.82 | 273.78 | 10.78 |
| **10** | 314.23 | 31.73 | 300.84 | 39.24 | 308.06 | 27.59 |
| **12** | 346.40 | 33.54 | 347.61 | 40.89 | 334.55 | 34.06 |
| **14** | 370.95 | 49.17 | 367.37 | 39.87 | 360.10 | 37.79 |
| **16** | 412.15 | 43.16 | 405.29 | 41.85 | 395.06 | 26.74 |
| **18** | 487.34 | 61.27 | 495.66 | 58.57 | 472.16 | 66.74 |
| **19** | 474.62 | 71.22 | 523.15 | 36.54 | 513.53 | 35.96 |
| **20** | 526.16 | 43.03 | 503.88 | 41.64 | 506.66 | 46.00 |
| **21** | 502.34 | 42.66 | 493.98 | 34.02 | 483.53 | 34.80 |
| **22** | 322.55 | 45.85 | 327.06 | 71.77 | 314.02 | 74.84 |
| **23** | 259.27 | 68.46 | 251.71 | 53.37 | 241.01 | 49.93 |

**Supplemental Table 2B.** Continuous TEER analysis of the Caco-2 cell monolayer (n = 12 used for each drug study) over 23 days was used to assess monolayer integrity (Caco-2-derived monolayers with IDs Caco-2#M1 to Caco-2#M36 were used).